Heart disease and cancer are the most common causes of morbidity and mortality in the United States and together account for 1,229,772 (or 46.8%) of all deaths. 1 Heart failure (HF) alone afflicts 6.5 million people in the United States. 2 Heart disease and cancer share multiple risk factors, such as age, tobacco use, diet, and lack of physical activity, and therefore the 2 conditions frequently coexist. In addition, many effective and life-prolonging chemotherapeutic agents may result in substantial cardiotoxicity leading to symptoms of cardiac dysfunction. 3 Over the past several years, the field of cardio-oncology has emerged with the aim of addressing the specific health needs of patients with cancer who are either at cardiovascular risk or have preexisting heart disease. The population of cardio-oncologic patients is expected to increase in the near future owing to our aging population. By the year 2030, the prevalence of HF is expected to increase by 46%, resulting in >8 million adults with HF. 2 Similarly, by 2020, the number of cancer survivors is projected to increase from 11.7 million in 2007 to 18 million. 4 Although multiple studies have evaluated the effects of comorbidities on the prognosis of various cancer diagnoses, none to our knowledge have specifically described the relationship between HF and the outcomes of patients with cancer hospitalized in the US. Understanding this relationship may provide insights and opportunities for improving care of patients with cancer. The present study explores the risk of comorbid HF on hospitalized patients with cancer. We describe the national burden of HF as well as characterize the hospital events, procedures, and outcomes for hospitalized patients with cancer.
Methods
The National Inpatient Sample (NIS) from the Agency for Healthcare Quality and Research (AHRQ) Health Care Utilization Project (HCUP) provides a representative sample of hospitalization administrative data in the US. For 2014, 20% of the 4,411 HCUP-participating hospitals were sampled, constituting an unweighted sample of >7 million hospitalizations. The unit of analysis in the NIS is a discharge; therefore, readmissions are not identified. The NIS sampling frame covers >95% of the United States population and >94% of all community hospital discharges. 5 All adult (age 18 y) patient hospitalizations with a primary cancer diagnosis were selected according to the Clinical Classification Software (CCS) principal diagnostic codes (online Supplemental Table 1 ). The CCS was developed by AHRQ as part of the HCUP to collapse International Classification of Diseases, 9th revision, clinical modification (ICD-9-CM) codes into clinically meaningful and more useable categories. 6 There were 16 cancer diagnoses in total: head and neck, gastrointestinal (GI), lung, breast, female reproductive system, male reproductive system, renal, bladder, thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, multiple myeloma, central nervous system (CNS), melanoma, and other unclassified malignancies. Patients with one of the following CCS codes were included in the "other cancer" category: 1) cancer, other and unspecified primary; 2) malignant neoplasm without specification of site; or 3) neoplasms of unspecified nature or uncertain behavior. In an effort to exclude elective admissions for low-risk surgical procedures, admissions categorized as elective and lasting <48 hours in duration requiring surgical procedures were removed from the sample. Hospitalizations for primary oncologic conditions were categorized into 2 groups, those without comorbid HF and those with HF, to compare patient and hospitalization characteristics between cohorts (online Supplemental Table 2 ). Selected comorbidities and inpatient procedures were identified according to relevant ICD-9-CM codes.
Outcomes of interest included hospitalization costs, length of stay (LOS), postdischarge disposition, and inpatient mortality. To characterize utilization of hospital services further, rates of multiple inpatient events were calculated including procedures and the diagnosis of circulatory shock. Procedures included were blood transfusions, inpatient chemotherapy, cardiac catheterization, dialysis, mechanical ventilation, continuous positive airway pressure, thoracentesis, tracheostomy, and bronchoscopy.
Analyses of the patient characteristics and hospitalization costs accounted for the survey design of the NIS. Patient characteristics for the sample were described accounting for survey weights and clustering of data to make national estimates. Differences between groups were tested with the use of t tests and chi-square tests as indicated by baseline characteristics. For the cost analysis, the NIS provides total charges, which reflect the amount a hospital billed for services, rather than actual costs or the amount a hospital received in reimbursement. To calculate costs, HCUP provides cost-to-charge ratio (CCR) adjustments. 7 A known limitation of hospital-specific CCRs is that they do not account for all cost variations derived from hospital charges. 8 Cost-to-charge estimation is improved with further adjustment accounting for specific diagnosis-related groups. 9 The NIS CCR costs were further adjusted with the appropriate adjustment factor for each discharge's Medicare severity diagnosis-related groups or CCS category to obtain the final hospitalization cost estimates. 8 Differences between the groups were compared with the use of t tests or chi-square tests as indicated.
Multivariable logistic regression analysis was performed to identify factors associated with inpatient mortality. Models accounted for NIS survey design and clustering and adjusted for age, sex, race/ethnicity, median household income, comorbid HF, Elixhauser comorbidity score, and the cancer type with the use of multivariable fractional polynomials for continuous risk factors. A graph of the curvilinear risk association between age and inpatient mortality, and between Elixhauser composite score and inpatient mortality is included in online Supplemental Figs. 1 and 2. The inpatient mortality odds ratios (ORs) based on cancer type were calculated with respect to a reference category, which was defined as the cancer type associated with the lowest inpatient mortality rate. Analyses were performed in Stata 15.1 (Statacorp, College Station, Texas). All estimation procedures were performed with the use of appropriate NIS survey weights to account for sampling design, and results are presented as the weighted national 2014 hospitalized population with the use of the Stata svyset estimation procedures. The Institutional Review Board provided exemption for this project. 10 
Results
In total, there were 899,640 hospitalizations with a primary oncologic diagnosis in 2014. Of those, 834,900 (92.8%) patient hospitalizations did not have documented comorbid HF and 64,740 (7.2%) documented a comorbid HF diagnosis. Patient characteristics are presented in Table 1 . Patients with HF were on average older than patients without HF (73.7 y vs 63.9 y). Patients with HF had more documented comorbidities during the hospitalization overall, with particularly high rates of hypertension (74.1% vs 53.1%; P < .001), coronary artery disease (46.0% vs 13.1%; P < .001), and diabetes mellitus (40.3% vs 23.4%; P < .001) compared with patients without HF. The most common oncologic diagnoses in patients with HF and without HF were GI (25.6% vs 26.1%; P = .2713), lung (17.7% vs 13.1%; P < .001), and other (24.4% vs 25.3%; P = .0542).
Estimated hospitalization costs, LOS, inpatient mortality, and disposition data are reported in Table 2 . The hospitalization cost and LOS for patients with HF were significantly higher than in patients without HF (mean adjusted cost $22,571 vs $20,234 [P < .001]; mean age-standardized LOS 12.7 d vs 8.2 d [P < .001]). The age-standardized inpatient mortality was 12.2% for patients with HF compared with 4.5% for patients without HF (P < .001). Patients with HF were more often discharged to a skilled nursing facility than patients without HF (27.5% vs 14.8%).
Overall, the age-standardized rates of circulatory shock and most inpatient procedures were higher in patients with HF than without HF (Table 3) . Otherwise, differences in inpatient chemotherapy and tracheostomies were not markedly different.
Patient factors associated with inpatient mortality are presented in Table 4 . Female sex was protective against inpatient mortality (OR 0.89, 95% confidence interval [CI] 0.85À0.93; P < .001). Presence of HF was associated with a higher risk of inpatient mortality (OR 1.12, 95% CI 1.04À1.20; P < .001). Adjusted ORs were most significant for the following cancers: lung (OR 4.67, 95% CI 2.96À7.37; P < .001), breast (OR 3.74, 95% CI 2.35À5.97, P < .001), non-Hodgkin lymphoma (OR 3.72, 95% CI 2.35À5.89; P < .001), and leukemia (OR 7.53, 95% CI 4.79À11.86; P < .001).
Discussion
This study describes the clinical characteristics, inpatient events, and outcomes of hospitalized patients with cancer and HF. Comorbid HF affects many patients with cancer (7.2%) who are admitted to the hospital with a primary oncologic diagnosis. Patients with cancer who have comorbid HF tend to be older, and commonly have a number of other comorbidities, including coronary artery disease, atrial fibrillation, hypertension, diabetes mellitus, chronic kidney disease, and chronic obstructive pulmonary disease. A comorbid HF diagnosis is associated with increased cost of hospitalization, LOS, and, most strikingly, a high inpatient mortality rate of 12.2%.
Comorbidities are important modifiers for the treatment and prognosis of cancer. Presence of multiple comorbidities has been associated with worse outcomes in multiple cancers, including breast cancer, 11 colon cancer, 12 and lung cancer. 13 For example, Yancik et al 11 evaluated the effects of comorbidities in 1,800 postmenopausal breast cancer patients. They found that comorbid conditions, such as diabetes, renal failure, stroke, liver disease, previous cancer, and smoking, predicted early mortality. In that study's patient population, the second most common cause of death after cancer was heart disease (17.1% of all deaths). They concluded that both age and comorbidity status influence the ability to obtain adequate cancer prognostic information, limit treatment options, and increase the chance of dying from a nononcologic cause. In less aggressive cancers, comorbidity plays an even larger role in predicting survival. 14 To our knowledge, the present study is the first to evaluate and characterize the national burden of HF among hospitalized oncologic patients. We found that the inpatient mortality rate of patients with cancer and HF (12.2%) is well above the average mortality rate of patients of a similar age admitted with acute decompensated HF (»4% mortality rate) 15 ; however, it is similar to the rate of inpatient mortality for HF patients who required treatment in the intensive care unit (»11% mortality rate). 15 HF may influence mortality rates for a number of reasons. First, as previously mentioned, HF alone is a significant cause of morbidity and mortality and can carry a prognosis similar to many cancers. 16, 17 In addition, HF often limits cancer treatment options because many chemotherapeutic regimens exacerbate or even cause cardiac dysfunction and acute cardiovascular events. For example, anthracyclines, trastuzumab, cyclophosphamide, 5-fluorouracil, and certain tyrosine kinase inhibitors all have a significant incidence of HF. 3 Other chemotherapeutic agents, such as cisplatin, nilotinib, and paclitaxel, are associated with acute coronary artery thrombosis. 18 Patients who receive suboptimal chemotherapy because of preexisting HF or from developing cardiotoxicity during treatment can be at high risk for poor outcomes.
Increasing efforts are being made to optimize the care of patients with cancer who have cardiovascular disease or have multiple cardiovascular risk factors both before and after cancer treatment. The American Heart Association recently published a scientific statement highlighting the preventive and treatment strategies for cardiovascular disease in breast cancer patients. 19 Recommendations for surveillance with the use of echocardiography and strain imaging for cancer patients receiving cardiotoxic chemotherapy have recently been published by the American Society of Echocardiography and the American Society of Clinical Oncology, which reflects the growing efforts to identify patients at risk for poor cardiac outcomes. 20, 21 Although progress has been made in recognizing the specific care needs of patients with cancer and comorbid cardiac disease, cardiovascular management of a patient with cancer continues to be complex because it depends on the type of cancer and the cardiotoxicity profile of the chemotherapeutic regimen as well as the patient's preexisting cardiovascular risk factors. In the present study, we show that hospitalized patients with cancer and HF have poor outcomes, thus highlighting a potential opportunity for improvement in multidisciplinary care.
Future research is essential to better understand how to screen and manage hospitalized high-risk patients with cancer. Whereas our analysis of the NIS database is based on administrative data, a clinical registry of patients may offer opportunities to analyze the correlation of hospitalization outcomes with biomarker profiles and specific chemotherapeutic agents. Similarly, the Nationwide Readmissions Database enables analyses of national readmission rates and can be used for future studies evaluating the effect of HF on readmission rates for cancer patients. The utility of simple interventions, such as early screening with cardiac biomarkers or imaging, or early involvement of the cardiology consulting team for hospitalized cancer patients with high cardiovascular risk, also warrants evaluation.
Study Limitations
These data represent hospitalization episodes and not unique patients. The diagnostic codes used to identify HF are highly specific with reasonable sensitivity (»65%) and a positive predictive value of »84%. 22 A clinical registry or cohort study may improve sensitivity to screen relevant patients for HF but would not provide the national scale of information provided through the NIS. This is a known shortcoming of administrative data from real-world patients. The NIS samples administrative data, so more detailed data regarding symptoms, vital signs, chemotherapeutic agents, and laboratory data are not available. In addition, data on HF etiology, ejection fraction, functional status, and medical therapy are not available. There are significant limitations regarding the diagnosis of cancer, the stage of disease, and time in the clinical course (newly diagnosed and localized vs advanced disease after multiple treatments). Patients with certain cancer diagnoses may be at a greater risk of mortality because of the intensity and modalities of therapy, and this information is not captured in the NIS database. The accuracy of diagnoses is dependent upon medical provider coding and certain diagnoses may be undercoded to a greater degree. Cost estimates are derived based on HCUP methodology and may not be accurate of true hospitalization costs. Although we used Elixhauser comorbidity scores to adjust for comorbid factors associated with HF, other conditions prevalent among HF patients may impart risk to oncologic patients which were not accounted for in the inpatient mortality regression model.
Conclusion
This study shows that cancer patients admitted to the hospital who have comorbid HF have higher costs, longer LOS, and high risk of short-term mortality. Prospective longitudinal studies are needed to further assess the additional burden of HF in cancer patients. It is unclear whether earlier recognition and treatment of HF can affect outcomes, but this warrants further investigation with a collaborative effort between oncologists and cardiologists.
